The Sucralfate 4% Gastric Tube Site Paste is a specially crafted topical formulation intended for the management of skin irritations, abrasions, and ulcerations at gastric tube sites. This paste is designed to adhere to the skin, forming a protective barrier that promotes healing and prevents further damage from the gastric tube's mechanical irritation. Its unique composition allows for easy application and adherence to the affected area, ensuring that the medication remains in place to exert its therapeutic effects.
While sucralfate is traditionally used for gastrointestinal ulcerations, this topical formulation is specifically tailored to treat skin conditions associated with the use of gastric tubes. It is not intended for the treatment of internal gastric conditions such as peptic ulcers. The Sucralfate 4% Gastric Tube Site Paste is ideal for patients who require long-term gastric tube placement and are at risk of developing related skin complications.

Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
The Sucralfate 4% Gastric Tube Site Paste is a specialized formulation designed for administration through a gastric tube, providing a unique solution for patients who are unable to take medications orally. This formulation is particularly beneficial in hospital settings or for individuals with swallowing difficulties. Sucralfate, the active ingredient in this paste, is a cytoprotective agent that works primarily in the lining of the stomach to treat and prevent ulcers.
Sucralfate acts locally by adhering to ulcer sites, creating a protective barrier against stomach acids, pepsin, and bile salts, which can exacerbate the ulcerative condition. This barrier promotes healing and shields the affected area from further irritation. The 4% concentration in the paste ensures that a sufficient amount of the drug is delivered directly to the site of action. The paste form is particularly advantageous for patients with nasogastric or gastrostomy tubes, as it can be easily administered without the need for swallowing.
This medication is commonly used in the treatment of peptic ulcer disease, including both gastric and duodenal ulcers. It is also beneficial in the management of gastroesophageal reflux disease (GERD) and may be used in the prevention of stress ulcers in critically ill patients. Additionally, Sucralfate has been found to be helpful in the treatment of mucositis and esophagitis, providing a soothing effect on the mucosal lining of the gastrointestinal tract.
For prescribers considering this formulation, it is important to note that Sucralfate should be used with caution in patients with renal impairment due to the risk of aluminum accumulation. Furthermore, the timing of administration is crucial, as Sucralfate should be given on an empty stomach, typically one hour before meals and at bedtime, to ensure optimal efficacy. Drug interactions can occur with certain medications, such as tetracycline antibiotics, so a thorough medication review is recommended before initiating therapy with Sucralfate.
Patients and prescribers interested in using the Sucralfate 4% Gastric Tube Site Paste can expect a formulation that is tailored for ease of use with gastric tubes, providing targeted relief and protection for various gastrointestinal conditions. If you have any questions or require further information about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is dedicated to providing comprehensive support and guidance to ensure the best possible outcomes for our patients.
Sucralfate is a medication primarily used to treat and prevent ulcers in the stomach and intestines. It works by creating a protective barrier on the ulcer site against stomach acid and enzymes, allowing healing to occur. When sucralfate is administered as a 4% gastric tube site paste, it is important to consider potential drug interactions that may affect its efficacy or the efficacy of other medications.
One of the key interactions to be aware of is with antacids. Sucralfate should not be administered simultaneously with antacids, as they may reduce its effectiveness. It is recommended to separate the administration of sucralfate and antacids by at least 30 minutes to 1 hour. Additionally, sucralfate can interfere with the absorption of certain drugs, such as tetracycline antibiotics, quinolone antibiotics (e.g., ciprofloxacin, levofloxacin), levothyroxine, phenytoin, digoxin, warfarin, and theophylline. To minimize this interaction, these medications should be taken at least 2 hours before or after sucralfate.
Proton pump inhibitors (PPIs) and H2 receptor antagonists may also interact with sucralfate. While these medications are often used in conjunction to manage gastrointestinal conditions, the timing of administration may need to be adjusted to ensure optimal absorption and therapeutic effect. It is generally advisable to administer PPIs or H2 antagonists at least 30 minutes before sucralfate.
It is also important to note that sucralfate can bind to dietary proteins and may interfere with the absorption of dietary nutrients when administered via a gastric tube. Nutritional supplementation may be necessary for patients on long-term sucralfate therapy. Additionally, sucralfate may alter the gastric pH, potentially affecting the solubility and absorption of other medications that are pH-dependent.
Patients with renal impairment should use sucralfate with caution, as it contains aluminum, which can accumulate in the body when renal function is compromised. This can lead to aluminum toxicity, particularly in patients on dialysis or those with severe renal dysfunction.
For patients and prescribers considering the use of sucralfate 4% gastric tube site paste, it is crucial to review all current medications, including over-the-counter drugs and supplements, to identify any potential interactions. Adjustments in dosing schedules or monitoring may be necessary to ensure safe and appropriate use of this medication. If you have any questions or require further information regarding drug interactions with sucralfate, please reach out to us at Bayview Pharmacy for personalized advice and support.
Sucralfate is a medication primarily used to treat and prevent ulcers in the upper gastrointestinal tract. Its mechanism of action is quite unique compared to other anti-ulcer medications. When sucralfate enters the stomach and comes in contact with acidic gastric juices, it undergoes a complex reaction where it forms a viscous, paste-like substance. This substance has an affinity for ulcerated or eroded areas of the gastric mucosa, where it adheres to the site, creating a protective barrier over the ulcer. This barrier serves two main purposes: it shields the ulcer from the corrosive effects of gastric acid and pepsin, which allows the ulcer to heal, and it also directly inhibits the action of pepsin, an enzyme that contributes to ulcer formation.
The Sucralfate 4% Gastric Tube Site Paste is specifically formulated for administration via a gastric tube. This is particularly beneficial for patients who are unable to take oral medications due to various reasons such as dysphagia (difficulty swallowing), unconsciousness, or those who have had certain surgeries that affect the oral intake of medications.
When administered, the sucralfate paste coats the lining of the stomach, adhering to the site of ulcers or erosions. By forming this protective layer, it not only promotes healing of existing ulcers but also helps to prevent new ones from forming. This is particularly important in patients who are at increased risk of developing ulcers due to factors such as prolonged bed rest, use of certain medications (e.g., NSAIDs), or those with existing gastrointestinal diseases.
It is important for both patients and prescribers to understand that while sucralfate can provide relief from ulcer pain and promote healing, it does not decrease stomach acid production. Therefore, it is often used in conjunction with other medications that do reduce acid production when necessary. Additionally, the timing of sucralfate administration in relation to other medications is crucial, as it can interfere with the absorption of certain drugs if taken simultaneously. Typically, it is recommended to administer sucralfate at least 2 hours before or after other medications.
For those interested in using the Sucralfate 4% Gastric Tube Site Paste, it is essential to follow the specific instructions for preparation and administration to ensure the medication is delivered safely and effectively. If you have any questions or require further information about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide the support and guidance needed to optimize patient care.
Sucralfate 4% Gastric Tube Site Paste is a specially prepared liquid medication that's applied through a gastric tube. It's used to safely deliver medication directly into the stomach for patients who are unable to swallow pills or liquids.
This medication is administered through a gastric tube, which is a medical device used to provide a direct route to the stomach for those who can't take medicines by mouth.
Sucralfate 4% Gastric Tube Site Paste is primarily used for patients with gastrointestinal conditions that require the protective properties of sucralfate. It helps to treat and prevent ulcers in the digestive tract.
While it is commonly used in hospital settings, it can also be used at home under the guidance and supervision of a healthcare provider who can provide proper instruction on how to use the gastric tube.
The administration of Sucralfate 4% Gastric Tube Site Paste via a gastric tube should not be painful. If the patient experiences discomfort, they should inform medical personnel as this may indicate a problem with the tube placement.
As with any medication, there could be side effects. Some side effects may include constipation, dry mouth, upset stomach, and dizziness. Any severe or persistent side effects should be reported to a healthcare provider.
The frequency of administration will be determined by the prescribing healthcare provider based on the patient's specific condition and treatment needs.
Yes, it can interact with other medications, which might alter their absorption or efficacy. Always inform your healthcare provider about all the medicines you are taking to avoid potential interactions.
It should be stored at room temperature, away from light and moisture, and kept out of reach of children and pets. Do not freeze or store it in the bathroom.
If a dose is missed, it should be given as soon as possible unless it is nearly time for the next scheduled dose. Do not double the dose to catch up. Always follow the advice of the healthcare provider managing the treatment.
Patient should not stop this medication without consulting their healthcare provider because sudden cessation might worsen their condition or cause the symptoms to return. A proper tapering plan may be necessary based on individual circumstances.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.